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With the impending crisis of antimicrobial resistance, there is an urgent need to develop novel antimicrobials
to combat difficult infections and MDR pathogenic microorganisms. DNA replication is essential for cell viabil-
ity and is therefore an attractive target for antimicrobials. Although several antimicrobials targeting DNA repli-
cation proteins have been developed to date, gyrase/topoisomerase inhibitors are the only class widely used
in the clinic. Given the numerous essential proteins in the bacterial replisome that may serve as a potential
target for inhibitors and the relative paucity of suitable compounds, it is evident that antimicrobials targeting
the replisome are underdeveloped so far. In this review, we report on the diversity of antimicrobial compounds
targeting DNA replication and highlight some of the challenges in developing new drugs that target this
process.
Introduction
The increase in MDR bacteria has resulted in limited treatment op-
tions, and therefore the development of compounds directed
against these microorganisms is of utmost importance. In recent
years, the pipeline of new antimicrobials has almost dried up, apart
from the approved follow-up compounds (second, third and fourth
generations), which have the same mode of action as their prede-
cessors.1 The development of antimicrobials derived from existing
scaffolds is not without risk, as these compounds may be vulner-
able to the same resistance mechanisms. Therefore, exploring
new potential targets and/or increasing structural diversity in the
next-generation antimicrobials are paramount in minimizing the
risk of rapid acquisition of antimicrobial resistance. There are sev-
eral essential cellular processes that can serve as targets for novel
antimicrobials and many of these are exploited by antimicrobials.
Of particular interest for this review is DNA replication. Correct repli-
cation of DNA by a multi-protein complex, the replisome, and pro-
teins associated with it (Table 1 and Figure 1) is an essential
requirement for cell viability. The ‘core’ replisome complex consists
of helicase, primase, DNA polymerase, sliding clamp, clamp loader
and single-stranded DNA-binding (SSB) proteins. Stringent coordin-
ation of this complex is essential for DNA replication, and inhibition
of the function of any of these proteins or their interactions in prin-
ciple disrupts the process and results in cell death.2 Other proteins
that are crucial for DNA replication include topoisomerase II and
DNA ligase.
Despite the potential of replication proteins to serve as a target
for antimicrobial compounds, clinical use has primarily been
limited to topoisomerase II inhibitors, which target DNA gyrase
and/or topoisomerase IV (TopoIV). In this review we will discuss in-
hibitors that target ‘core’ replisome proteins as well as associated
proteins that are crucial for DNA replication. We illustrate three key
challenges (antimicrobial resistance, specificity and exploration of
new targets) and potential strategies to meet these challenges
using examples of novel DNA replication-targeting antimicrobials
active against Clostridium difficile and other MDR pathogens.
Clinically used antimicrobials targeting DNA
replication: topoisomerase II inhibitors
The two bacterial topoisomerase II enzymes – DNA gyrase and
TopoIV – modify the topology of DNA during replication.3 Gyrase
and TopoIV are tetramers composed of two GyrA and two GyrB
subunits (encoded by gyrA and gyrB) or two ParC and two ParE
subunits (encoded by parC and parE), respectively.4,5 Despite
structural similarities,3 the two topoisomerase II enzymes per-
form distinct functions in prokaryotes. Gyrase is able to intro-
duce negative supercoiling into DNA, thereby relaxing the DNA
helix, while TopoIV is specialized in DNA decatenation and
unknotting of DNA.6–8 Some bacteria only encode gyrase in their
genome; it is possible that gyrase in these bacteria can effi-
ciently decatenate DNA without TopoIV, as was shown with
Mycobacterium smegmatis.9
Existing topoisomerase II inhibitors can roughly be divided into
(i) ATPase inhibitors and (ii) topoisomerase II poisons that interfere
with the catalytic DNA cleavage/joining process.10 The first group is
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represented by the aminocoumarin class and the second group by
the fluoroquinolones (FQs).
Aminocoumarins, such as the naturally occurring novobiocin,
are cyclic peptides that compete with ATP to bind GyrB.4,11
Though novobiocin has little structural similarity with ATP, the
binding sites of the drug partially overlap with the binding sites of
ATP in GyrB.12 Due to this overlap, mutations that confer amino-
coumarin resistance are likely to affect the enzymatic activity of
Table 1. Diversity of targets in the bacterial DNA replication machinery






DnaA DnaA CD0001 initiation of DNA replication
at oriC
Replicative helicase DnaB DnaC CD3657b unwinding of double-stranded
DNA at the replication fork
Replicative helicase
loader
DnaC DnaI CD3654b required for functional loading
of the replicative helicase





Primosome protein – DnaD CD3653 initiation of DNA replication
through interactions with
other initiation proteins, ori-
gin remodelling
Primase DnaG DnaG CD1454b synthesis of primers on the
lagging strand
Primosomal protein N0 PriA PriA CD2586
Sliding clamp b (DnaN) DnaN CD0002 griselimycins







DNA polymerase III a
subunit DnaE
DnaE DnaE CD3396 elongation of leading and lag-
ging strand during DNA
synthesis (E. coli); initial ex-
tension of the RNA primers
on the lagging strand (B.
subtilis)
guanine inhibitors
DNA polymerase III a
subunit PolC
– PolC CD1305 elongation of both leading





DNA polymerase I PolA PolA CD1128 removal of RNA primers and
gap filling





Topoisomerase IV ParE, ParC ParE, ParC – FQs, NBTIs




SSB protein SSB protein SSB protein CD3662, CD3235 preventing degradation of sin-





oriC, chromosomal origin of replication.
aPutative; most replication proteins of C. difficile are not characterized (apart from PolC).91
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the topoisomerase.10 Novobiocin was licensed for treatment of in-
fections by staphylococci and other susceptible organisms, but the
clinical use of aminocoumarins is very limited due to poor pharma-
cological properties (e.g. poor solubility, poor absorption). Though
improvement of pharmacological properties may yield clinical can-
didates, none has entered trials yet.13
FQs are the most successful class of antimicrobials targeting
DNA replication and among the most widely used antimicrobials
on the market.2 The FQ mode of action is to stabilize cleaved DNA–
topoisomerase II complexes, thereby increasing the number of
double-stranded DNA breaks in the bacterial cell.14,15 Rapid cell
death induced by FQs is likely the consequence of chromosome
fragmentation, while inhibition of DNA replication results in
reduced cell growth instead of cell death.14 Most FQs are able to in-
hibit both gyrase and TopoIV with different efficiencies, with actual
target preference depending on the specific compound and the
bacterial species against which it is used.14,16–18
A major concern is the rise of FQ-resistant pathogens. FQs are
commonly used to treat infections by Enterobacteriaceae, non-
fermenting Gram-negative bacilli (in particular Pseudomonas
aeruginosa and Acinetobacter baumannii) and Mycobacterium
tuberculosis,19,20 but resistance can also occur when FQs are used
to treat infections with a different pathogen. For instance,
increased use of FQs and simultaneous development of FQ resist-
ance in clinical isolates of C. difficile resulted in the emergence of
the epidemic PCR ribotype 027, as evidenced by whole-genome se-
quence data,21,22 even though FQs are not the drug of choice to
treat C. difficile infections. FQ resistance is mainly acquired through
mutations in the so-called quinolone resistance-determining
regions (QRDRs) of the gyrase and/or TopoIV genes.23 In most re-
sistant pathogens the mutations are located in gyrA and/or parC,
and rarely in gyrB or parE. In most Gram-positive bacteria, TopoIV
is the primary target for FQs and resistance mutations arise first in
parC. In contrast, mutations in most Gram-negative bacteria occur
first in gyrA.24 Single-step mutations can lead to resistance and
the C. difficile example illustrates how such a single mutation can
fuel an epidemic with detrimental clinical outcome. FQ resistance
can also be conferred by non-specific efflux systems that can ex-
port quinolones and other antimicrobial agents or by plasmids har-
bouring a quinolone resistance determinant.19
Antimicrobials targeting DNA replication
under development
There are many different compounds that have been identified as
DNA replication inhibitors with potential to be used as an anti-
microbial. These have been comprehensively reviewed else-
where.2,25 Here, we discuss several classes of DNA replication
antimicrobials to highlight the diversity of replication proteins that
can be exploited as targets and indicate some of the new
developments.
Novel bacterial topoisomerase inhibitors (NBTIs)
Increasing FQ resistance has spurred the development of novel
topoisomerase inhibitors that are active against FQ-resistant
gyrase or TopoIV. Besides modifying existing FQ scaffolds,26 novel
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Figure 1. Schematic representation of the variety of targets of antimicrobials in the bacterial replisome. Indicated is the core of the replisome and
the other proteins that have been targeted by antimicrobial compounds. For simplicity, replication initiation proteins and regulators have been omit-
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called NBTIs, have been developed.13 Antimicrobials of this class
target the catalytic core of topoisomerase, as do FQs, but NBTIs
have a different mode of action. For example, the NBTI
GKS299423 (GlaxoSmithKline) was shown to stabilize a pre-
cleavage complex, in contrast to the cleavage complex with
double-stranded DNA breaks targeted by FQs.27 Examples of other
NBTI compounds are a series of pyrazole derivatives and related
tetrahydroindazoles,28 NXL101,29 NBTI 5463,30 gyramides
(N-benzyl-3-sulfonamidopyrrolidines),31 and ACT-387042 and
ACT-292706.32 None of these compounds has entered clinical tri-
als yet.
DNA ligase inhibitors
The primary function of bacterial NAD!-dependent DNA ligase
(LigA) is to join the Okazaki fragments for the completion of lag-
ging-strand DNA replication synthesis.33 It is an attractive target
for the development of novel antimicrobials as the ligase gene is
present in all bacterial genomes and was found to be essential in
several key pathogens.33,34 It shares limited similarity to eukary-
otic DNA ligase34,35 and the binding of NAD! as a substrate for lig-
ase activity is a unique feature of bacterial ligase, limiting the
potential for toxicity in humans.
All ligase inhibitors that have been developed to date are com-
petitive inhibitors that bind a hydrophobic pocket near the binding
site of the NAD! substrate.36 Four predominant classes of LigA in-
hibitors have been identified and here we will focus on the two
most promising classes, the 2-amino-[1,8]-naphthyridine-3-
carboxamides (ANCs) and the adenosine analogues.36
The ANC scaffold was identified in high-throughput screening
against Escherichia coli LigA (IC50 of 25 lM), but displayed better
activity against Staphylococcus aureus LigA (IC50 of 2.5 lM).
37 The
compound was not active against WT E. coli cells, however, due to
poor permeability and efflux. Optimization of the ANC scaffold
yielded compounds with improved activity (MIC 1–8 mg/L) against
primarily Gram-positive pathogens (including MRSA and C. difficile),
and promising results in animal models.37
Adenosine analogues were identified in high-throughput screen-
ing for inhibitors of Haemophilus influenzae LigA.38,39 Biochemical
experiments and X-ray crystallography showed that this class of
compounds competes with NAD! and blocks the AMP-binding
pocket of the LigA adenylation domain. Adenosine analogues dis-
played good antimicrobial activities against both Gram-positive and
Gram-negative bacteria in vivo (MIC 1–8 mg/L).38 The initial adeno-
sine analogues had favourable pharmacological properties (mainly
good solubility) and one compound showed promise in S. aureus
thigh infection and Streptococcus pneumoniae lung infection animal
models.38 However, the adenosine analogues were rapidly cleared
in rats due to metabolism by cytochrome P-450s.39,40 Despite at-
tempts to optimize the solubility, antimicrobial activity and clear-
ance of these compounds, there are no reports published on further
progress.
Although the hydrophobic pocket near the binding site of the
NAD! substrate enables specific inhibition of the bacterial LigA by
competitive inhibitors, it is not directly engaged in interactions
with the NAD! substrate.33 A spontaneous resistant mutant of
S. aureus contains a single leucine-to-phenylalanine mutation in
the hydrophobic pocket that does not affect the ligase activity of
the LigA mutant, but leads to a significant loss of target binding by
adenosine analogues.33,38 This relatively high risk of resistance
against this class of compounds may have contributed to the fact
that no LigA inhibitors have been entered into human trials to
date.
DNA polymerase III inhibitors
The bacterial DNA polymerase III a subunit (PolIII) is an essential
enzyme for DNA replication as it is responsible for the synthesis of
DNA and its potential as an antimicrobial target has been noted in
recent in silico analyses of E. coli O157:H7 and M. tuberculosis.41,42
Moreover, the distribution of two different homologues of the a
subunit, PolC and DnaE, between Gram-positive and Gram-
negative bacteria presents an opportunity to develop inhibitors
specific to either group.43 The first inhibitor of PolIII,
6-(p-hydroxyphenylazo)uracil (HPUra), was identified in 1970.44
The majority of PolIII inhibitors specifically target PolC of low-G!C
Gram-positive bacteria. Indeed, the single DnaE-specific com-
pound reported to date (324C) did not demonstrate any in vivo
antimicrobial activity against Bacillus subtilis, while it was highly ac-
tive against purified B. subtilis DnaE in vitro.45 The reason(s) for this
is (are) unclear.
PolIII inhibitors can be categorized into three main classes:
(i) the 6-anilinouracils (AUs); (ii) the guanine inhibitors; and (iii) the
non-nucleobase inhibitors. The AU class of PolIII inhibitors, which
includes HPUra, is composed of a uracil-containing base-pairing
domain that binds the DNA at cytosine bases and an aryl domain
that determines the selectivity and affinity for PolC.46 AUs com-
petitively inhibit PolC with respect to dGTP through simultaneous
binding to the cytosine of the DNA strand and near the active site
of PolC, resulting in a ternary inactive complex of AU inhibitor, DNA
and PolC.46,47 HPUra served as a scaffold for the development of
numerous AUs with a broad range of antimicrobial and pharmaco-
logical properties. Two promising AUs, 6-(3-ethyl-4-methylanilino)
uracil (EMAU) and 6-([3,4-trimethylene]anilino) uracil (TMAU),
were highly active against PolC in vitro, but required optimization
to increase activity against various Gram-positive bacteria, includ-
ing MRSA.46,48–50 Improvement of solubility of AUs compromises
antimicrobial activity, but allowed the production of compounds
that could be delivered intravenously rather than subcutaneously
in animal models of infection.46,50–52 The frequencies of mutations
leading to AU resistance ranged from 3.6%10#10 to 1.2%10#8,
comparable to the frequency of ciprofloxacin resistance.53 All mu-
tations that conferred AU resistance were located at a specific
amino acid in the presumed dNTP/AU-binding site of PolC.53,54
Unexpectedly, however, the polymerase activity of these mutant
PolC enzymes was unchanged in comparison with the WT in vitro.
The guanine inhibitors of bacterial DNA polymerase III have a
purine moiety as the base-paring domain instead of the uracil ring
of the AUs. They act via the same active site-directed competitive
inhibition as AUs, but are active against both PolC and DnaE.47,55,56
Two lines of guanine inhibitors have been developed: the
N2-(3,4-dichlorobenzyl) guanines (DCBGs) and the N2-(3-ethyl-4-
methylphenyl)guanines (EMPGs). N7-substituted DCBGs and
EMPGs displayed potent in vitro antimicrobial activities against sev-
eral Gram-positive pathogens, but showed limited efficacy in ani-
mal models.47,56 Similar to the AUs, the DCBGs have poor solubility













 user on 12 January 2021
The non-nucleobase class of DNA polymerase III inhibitors in-
cludes anilinopyrimidinediones (APs) and quinazolin-2-ylamino-
quinazolin-4-ols (BisQuinols). The APs are structural isomers of AUs
and are also competitive inhibitors of dGTP.57 They show minimal
cytotoxicity and moderate antimicrobial activities (MIC ranging
from 8 to 16 mg/L).57 In contrast to AUs and APs, BisQuinols have
been suggested to compete with the DNA template, rather than
nucleotides.58 Though BisQuinol analogues were able to inhibit
Gram-positive pathogens, they were unselective for mammalian
Pold, which raises concerns about cytotoxicity.
There is no information on resistance development against the
guanine inhibitors or non-nucleobase inhibitors, but considering
the similarities in mode of action to the AUs, caution is warranted.
Inhibitors of other replication-related proteins
The sliding clamp, or b subunit, of the replication machinery, is a
polymerase processivity factor.59,60 The protein can be targeted by
novel griselimycins.61 Griselimycin is a natural product of
Streptomyces griseus with specific activity against the
Corynebacterineae suborder, including Mycobacterium species.62
The development of this class of compounds as anti-tuberculosis
drugs was initially abandoned as rifampicin became available for
treatment, but was revisited in light of its activity against drug-
resistant isolates.63 Poor pharmacokinetic properties of griselimy-
cin were addressed by the total synthesis of derivatives.61 In
particular, cyclohexylgriselimycin was highly active against
M. tuberculosis in vitro and in a mouse model of infection, compar-
able to isoniazid. Evidence for the mechanism of action came from
observations that the griselimycin biosynthetic operon contains a
sliding clamp homologue capable of conferring resistance to a sus-
ceptible Streptomyces strain, the selective amplification of a dnaN-
containing chromosomal fragment in mycobacterial strains with
evolved resistance (i.e. resistant strains harbouring multiple copies
of the dnaN gene), and the crystal structure of griselimycin in com-
plex with DnaN.61
Single-stranded DNA at the replication fork is stabilized and pro-
tected by SSB proteins.64 These proteins are also an integral part of
nucleoprotein complexes involved in recombination and re-
pair.65,66 Although present in all domains of life, the amino acid se-
quence, subunit composition and oligomeric state of these
proteins differ substantially between organisms.65 The essential
role of SSB protein–protein interactions and low sequence similar-
ity between eukaryotic and prokaryotic SSB proteins allows the po-
tential development of SSB protein–protein interaction inhibitors
that could serve as novel antimicrobials.66 Indeed, small mol-
ecules that interfere with the interaction between SSB proteins
and one or several binding partners have been identified by a high-
throughput fluorescence polarization assay.66,67 Inhibition by
these compounds is based on mimicking the SSB protein
C-terminus, which acts as a platform for interaction with other pro-
teins, or more targeted inhibition of the SSB protein/exonuclease I
(binding partner) interface.66
Challenges in developing novel antimicrobials
targeting replication
We consider three main challenges in the development of
novel antimicrobial compounds. First, novel antimicrobials should
overcome resistance to known drugs and minimize development
of resistance against the new drug. Second, they should preferably
be specific to the microorganism/pathogen of interest to prevent
dysbiosis of the host microbiome. The third challenge is to move
away from modification and optimization of existing scaffolds that
inhibit established cellular targets and explore novel targets and
mechanisms of action. In the following section, we illustrate these
challenges with a focus on compounds inhibiting the MDR organ-
ism C. difficile.
Challenge: antimicrobial resistance
The use of any antimicrobial agent exerts a selective pressure on
susceptible bacterial populations, thereby creating an environ-
ment where the development of antimicrobial resistance is se-
lected for. It can be assumed that resistance to any antimicrobial
is unavoidable. Though resistance is reported to nearly all of the
discussed replication antimicrobials, the likelihood of developing
resistance varies greatly between classes. For example, mutations
that confer resistance to LigA inhibitors do not affect the activity of
the enzyme, while most mutations leading to aminocoumarin re-
sistance impair gyrase functioning. Both antimicrobials target the
active site of their target enzymes, but the binding sites of LigA in-
hibitors are located in a region that is not directly involved in sub-
strate (NAD!) binding of LigA. Antimicrobials targeting DNA
replication proteins that bind their targets at the active site, such
as the aminocoumarins, have a relatively low risk of resistance,
since mutations that affect drug–protein binding tend to lead to a
non-functional protein.
LigA inhibitors, PolC inhibitors and most aminocoumarins target
one specific protein and therefore a single mutation is frequently
sufficient to cause resistance. FQs are able to target both gyrase
and TopoIV. As a result, a high level of FQ resistance usually re-
quires the presence of mutations in both gyrase and TopoIV,68
which reduces the risk of resistance development. However, vari-
ations in the potency of FQs against gyrase and TopoIV still enable
the emergence of resistant bacteria,14 and for organisms that only
have gyrase encoded in their genome, such as C. difficile, a single
mutation is still sufficient to cause resistance. Indeed, a single mu-
tation in gyrA (Thr82Ile) was most frequently found in FQ-resistant
clinical C. difficile isolates.69
Two promising strategies that might reduce development of
resistance (and cross-resistance) are (i) to target multiple pro-
teins in the bacterial cell, using so-called hybrid antimicrobials,
or (ii) to use multiple binding sites in a single target. Multi-
targeting reduces the chance of resistance development and
results in compounds that remain active against mutants resist-
ant to either one of the parent compounds. Though polyphar-
macological modelling and rational design of multi-targeting
drugs is a major challenge,70,71 interesting progress has been
made in recent years.
In FQ hybrid antimicrobials, a FQ moiety is covalently linked to
another pharmacophore, with a distinct cellular target.72 Various
FQ hybrid classes have been developed, but of particular interest
here are the AU–FQ hybrids, since both moieties target DNA
replication. The AU–FQ hybrid class was created by linking various
FQs to the N3 of the PolIIIC inhibitor HB-EMAU, with different link-
ers to modulate antimicrobial activity and pharmacological prop-
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bacteria, and some compounds had moderate activity against the
Gram-negative E. coli. MBX-500, one of the best AU–FQ hybrids, dis-
played 3-fold stronger inhibition of B. subtilis PolC than the AU moi-
ety alone, while it showed 5- to 10-fold less potent inhibition of
B. subtilis TopoIV and gyrase in comparison with the FQ compo-
nent.74 Despite these differences in target inhibition, MBX-500 had
strong antimicrobial activities against Bacillus species (MIC of
0.156 mg/L), S. aureus strains (MIC ranging from 0.625 to 5 mg/L)
and various other Gram-positive bacteria. As expected, MBX-500
retained high antimicrobial activity against strains that were resist-
ant to the FQ component. Resistance to MBX-500 was only found
in an AU- and FQ-resistant S. aureus that carried mutations in both
targets, thereby providing evidence that MBX-500 truly acts via a
dual-targeting mechanism. Indeed, the spontaneous mutation
frequency against MBX-500 was low (,5.6%10#10 at 4%MIC); no
resistant S. aureus strains could be isolated after a single passage,
whereas S. aureus did develop resistance against the individual AU
and FQ components.74 The antimicrobial properties of MBX-500
were also investigated in C. difficile,75 where FQ resistance is wide-
spread among clinical strains.69 The compound was active against
a panel of 30 C. difficile isolates (MIC range 1–4 mg/L), which
included several multiresistant strains and isolates from the epi-
demic PCR ribotype 027. Thus, dual-target antimicrobials are
promising for the fight against resistant pathogens, and the low
mutation frequencies (e.g. no spontaneous resistance) indicate a
possible reduced risk of resistance development in comparison
with single-target compounds.
Another approach to avoiding cross-resistance and reducing
the risk of resistance is to identify multiple (novel) binding sites
or multiple modes of action in a single established target, as
exemplified by the novel topoisomerase II inhibitor kibdelomy-
cin.76 Biochemical studies in S. aureus showed that kibdelomy-
cin is a potent ATPase inhibitor of both topoisomerase II
enzymes, although it is .80-fold more active against the
ATPase subunit of gyrase than TopoIV. The co-crystal structures
of kibdelomycin bound to the N-terminal domains of S. aureus
GyrB and ParE revealed a novel mode of ‘dual’ ATPase inhibition
by blocking ATP binding and destabilizing GyrB/ParE subunit di-
merization.77 Kibdelomycin displays strong antimicrobial activ-
ities against predominantly Gram-positive bacteria, including
MRSA and C. difficile.78,79 The MIC90 for C. difficile was 0.5 mg/L,
similar to the novel therapeutic fidaxomicin, but more potent
than metronidazole and vancomycin.78 Importantly, kibdelo-
mycin was equally active against FQ-resistant and -susceptible
strains and showed favourable pharmacokinetics in mice
and promise in a hamster model of C. difficile infection.78
Kibdelomycin also retained antimicrobial activity against
S. aureus strains resistant to novobiocin and coumermycin A1,
two known ATP inhibitors of topoisomerase II, and showed a
low frequency of resistance development (,5.4%10#10).76 The
MIC of kibdelomycin for a coumermycin-resistant S. aureus
strain carrying three mutations in GyrB was modestly increased
from 1 to 4 mg/L relative to the susceptible WT strain. This was
attributed to one of the three mutations (Ile175Thr) in GyrB,
which also interfered with kibdelomycin binding. Although the
reduced susceptibility of the coumermycin A1-resistant strain
warrants some caution, the data suggest that complete resist-
ance caused by a single point mutation is not likely to occur due
to the dual binding mode of this compound.
Challenge: specificity of novel antimicrobials
The normal gut microbiota is a diverse community of microbes
that lives in a complex ecological system with its host.80 With
the increasing knowledge on interactions and dynamics of the
microbiota with its host, it becomes evident that the human
microbiome is of great importance for the prevention and treat-
ment of infectious diseases. It can act as a protective barrier that
prevents colonization of the gut by non-commensal pathogens
and opportunistic pathogens that are already present. This so
called colonization resistance81 is greatly influenced by the di-
versity of the gut microbiota. Many broad-spectrum antimicro-
bials used in the clinic are known to affect the composition of the
gut microbiota.82,83 Colonization of the gut by pathogenic C. diffi-
cile is believed to require the disruption of the gut micro-
biota,84,85 and patients with recurrent C. difficile infection (CDI)
have a reduced diversity of their microbiota compared with
healthy controls and patients with initial CDI.86 There is a strong
association between the use of broad-spectrum antimicrobials
and increased risk of (recurrent) disease.87,88 Patients treated
with the narrow-spectrum antimicrobial fidaxomicin had lower
C. difficile recurrence rates in comparison with broad-spectrum
vancomycin,89 which was attributed to the minimal impact of
fidaxomicin on the gut microbiota, especially on bacteria of the
Bacteroides cluster, clostridial cluster XIVa and bifidobacte-
ria.89,90 The example of C. difficile underscores that it is desirable
for novel antimicrobials to limit the impact on the human micro-
biota as a whole.
Two strategies to generate or identify compounds with a nar-
row spectrum are (i) to test derivatives of an existing inhibitor for
increased specificity and (ii) to screen for compounds with select-
ive inhibition of a specific pathogen.
The first strategy has been used to identify and develop PolC in-
hibitors with increased species specificity. Many PolC inhibitors
have a broad Gram-positive spectrum and are therefore likely to
significantly affect the composition of the microbiota. However,
the isolation and purification of the C. difficile PolC as well as poly-
merases from various other organisms enabled the identification
of a series of novel 7-substituted DCBG inhibitors that showed im-
proved potency and specificity against C. difficile.91 One of these
compounds, 362E, showed potent antimicrobial activity against
C. difficile strains, similar to the first-line therapeutics metronida-
zole and vancomycin (MIC90 of 4 mg/L).
91,92 Limited in vitro tests
indicated that 362E is inactive against certain other Gram-positive
anaerobes,91 but the impact of 362E on the gut microbiota has not
been reported to date. 362E protected hamsters from death due
to C. difficile similarly to vancomycin and, though recurrent CDI
was observed in both treatment groups when animals were
treated for 3 days, prolonged treatment with 362E resulted in a
reduced recurrence rate.92 Further experimental evidence is
needed to confirm the selectivity of this compound for C. difficile
during in vivo treatment.
A second approach is to screen compounds de novo for specific
activity against certain pathogens and couple this to an assay to
determine the desired mode of action. SMT19969 (ridinilazole) is a
bis(4-pyridyl)bibenzimidazole that has been specifically developed
as a novel front-line antimicrobial for CDI treatment (MIC 0.06–
0.5 mg/L)93,94 with a low chance of resistance development.95
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bisbenzimidazole class were shown to bind the minor groove of
the DNA duplex and are thought to inhibit DNA replication through
inhibition of DNA helicases and/or topoisomerases.96 SMT19969
showed high selectivity for C. difficile relative to other intestinal iso-
lates during in vitro susceptibility testing. In a Phase I clinical trial,
treatment with SMT19969 resulted in minimal changes in the
composition of the faecal microbiota of healthy human subjects,
except for a significant reduction in total clostridial count,97 and
this was confirmed in an in vitro gut model of CDI.98 SMT19969
was superior to vancomycin and, in a subset of strains, to fidaxomi-
cin in a hamster model of recurrent CDI.94,97 A clinical Phase II trial
is currently ongoing where the efficacy of SMT19969 treatment
will be compared with that of vancomycin treatment in CDI pa-
tients. In another example, as discussed above, kibdelomycin
showed potent antimicrobial activities against a large panel of
C. difficile isolates.78 In contrast to metronidazole, kibdelomycin is
mostly inactive against Gram-negative anaerobes, including the
Bacteroides fragilis group, similar to the narrow-spectrum drug
fidaxomicin.78 The narrow spectrum of fidaxomicin is believed to
contribute to its favourable characteristics in treating recurrent
CDI,89 but the effect of kibdelomycin on recurrent disease has not
been investigated yet. MBX-500 also had little activity against
most Gram-negative anaerobes, and was selectively active
against C. difficile strains among Gram-positive anaerobes.75 MBX-
500 was shown to be efficacious in a gnotobiotic piglet model of
acute CDI, with a 100% survival rate and only mild CDI symp-
toms.99 Though the efficacy of MBX-500 was comparable to that
of vancomycin in a hamster model of CDI, it was superior in a mur-
ine model of recurrent CDI and associated with improved weight
gain in both animal models.75 The weight gain of infected animals
treated with MBX-500 and the results in the murine model suggest
that this compound might have a low impact on the gut
microbiota.
Narrow-spectrum antimicrobials are useful to prevent or treat
opportunistic infections, such as CDI, that are associated with dys-
biosis of the microbiome. Careful assessment of the effects on
microbiota should be considered for all antimicrobials developed
in the future.
Challenge: identifying novel targets in the
bacterial replisome
Despite the success of the FQs, the number of compounds target-
ing DNA replication in clinical use or development is relatively low
compared with inhibitors of other cellular processes, such as pro-
tein synthesis. Why is this group of antimicrobials underdeveloped,
considering that there are many more proteins in the bacterial
replisome?
A major issue is the poor characterization of the DNA replication
machinery of important pathogens. For instance, the DNA replica-
tion proteins in C. difficile are merely predicted through homology
with proteins in other organisms (Table 1), but functional evidence
is limited to C. difficile PolC so far.91 It can be expected that the ex-
tensive biochemical and structural characterization of replisome
proteins of drug-resistant pathogens might lead to the identifica-
tion of unique features that can be used to design antimicrobials
that specifically target this specific species.
Another possible explanation for the underdevelopment of
antimicrobials targeting DNA replication is that screens for
replication inhibitors have been notoriously difficult. Most inhibi-
tors are evaluated through in vitro biochemical assays that
measure inhibition of either enzymatic activity or DNA replica-
tion and these are not always suitable for high-throughput
screening.25 Moreover, compounds identified this way may dis-
play potent in vitro activity, while they have no activity against
bacterial cells in vivo due to undesirable pharmacokinetic prop-
erties. Besides some of the examples mentioned (aminocou-
marins, ANCs and PolIII inhibitors), this is illustrated by two
studies on inhibitors of the bacterial primosome.100,101 Inhibitor
peptides that target the DnaB–DnaG helicase–primase complex
in Bacillus stearothermophilus were able to inhibit purified pro-
teins in vitro,100 but were inactive in vivo. A highly active triami-
notriazine inhibitor of the P. aeruginosa replicative helicase
DnaB did not show antimicrobial activity towards WT P. aerugi-
nosa or E. coli, showed poor activity against S. aureus and
showed problematic toxicity towards mammalian cells.101 To
circumvent the limitations of biochemical assays, screening
could be performed using a whole-cell assay. By limiting the lev-
els of a certain replisome protein or affecting its function in
cells,102,103 screens can be enriched for compounds that target
DNA replication. A successful application of a whole-cell screen
is the identification of vibrepin as an inhibitor of DNA replication
in Vibrio.103 Vibrio species, including the causative agent of chol-
era (Vibrio cholerae) have a bipartite genome, where replication
of the second chromosome is dependent on the replication initi-
ator RctB. In the screen, the growth of an E. coli strain harbour-
ing an RctB-dependent plasmid with an antimicrobial resistance
determinant was evaluated in the presence and absence of the
antimicrobial and inhibition of growth was indicative of an RctB
inhibitor. Vibrepin was found to interfere with chromosome II
origin opening by RctB in vitro and inhibited various Vibrio spe-
cies (MIC 0.4–2.0 mg/L), but also inhibited various other species
via an RctB-independent mechanism.103 This example also illus-
trates how differences between replication machineries can be
exploited to work towards species-specific antimicrobial
compounds.
Outlook
Despite the challenges that are discussed with respect to anti-
microbials targeting DNA replication, we feel it is important to
focus research on the identification of novel therapeutic targets
in the bacterial replication machinery, whether they are individ-
ual proteins or protein–protein interactions,25 for several rea-
sons. First, DNA replication is essential for cell viability and
inhibiting any essential protein would be detrimental for cell
survival. Second, most components of the bacterial replisome
are substantially different from their eukaryote counterparts
and can therefore be exploited to develop compounds with min-
imal cytotoxicity. Third, antimicrobials directed at novel targets
are likely to avoid existing resistance mechanisms. And finally,
some components are well conserved between most bacteria,
such as the DNA initiator protein DnaA, while others are more re-
stricted to certain species Therefore, the bacterial replisome can
be used to develop both broad- and narrow-spectrum anti-
microbials. Recent insights on the structure of several DNA repli-
cation proteins and their inhibitors and the development of new
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DNA replication are expected to influence the rate of success of
this class of antimicrobials considerably.2
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